The MEA biobanking market size surpassed USD 4.16 billion in 2025 and is predicted to reach around USD 11.29 billion by 2035, registering a CAGR of 10.5% from 2026 to 2035. The market is mainly fueled by increasing investments in precision medicine, a high rate of chronic and genetic diseases, and strong government efforts to improve healthcare infrastructure.

MEA Biobanking Market Statical Scope

The MEA Biobanking Market is seeing notable growth, as it acts as the vital foundation for local genomic research, personalized medicine, and combating chronic and infectious diseases. By collecting and studying relevant biospecimens , biobanks in this area enable researchers to create targeted treatments for issues affecting local populations. As investments in biotech and pharmaceuticals rise in the Middle East, biobanks offer the organized, secure storage necessary for drug discovery, preclinical research, and clinical trials.

The use of AI, automation, and virtual biobanking in the MEA enhances the efficiency of sample storage, retrieval, and data analysis. Initiatives like the Emirati Genome Programme and the Qatar Genome Programme depend on strong biobanking systems to build extensive genetic datasets.

MEA Biobanking Market Share, By Sample Storage, 2025 (%)

• Blood - Holding a 55% share, the blood segment is dominating in the MEA biobanking market as it is the most commonly used biospecimen, providing a flexible and easily accessible resource for genomic and proteomic studies. Its dominance in the market stems from the strong demand for research on infectious diseases, chronic illnesses, and the development of personalized treatments.
• Cells & Tissues - Accounting for a 35% share, the Cells & Tissues segment is crucial in the MEA biobanking market, with significant growth expected as the region shifts towards precision medicine and regenerative therapies. Human tissues represent the largest revenue share, driven by a strong emphasis on cancer research and chronic disease management.

MEA Biobanking Market Share, By Application, 2025 (%)

• Regenerative Medicines - Holding a 38% share, the regenerative medicine segment plays a dominant role in the MEA biobanking market as it tackles significant regional health challenges like diabetes, cancer, and genetic disorders through advanced cell therapies and tissue engineering. This segment, including stem cell therapy, gene therapy, and tissue engineering, is rapidly expanding in the MEA region.
• Life Science - Accounting for a 50% share, the Life Science segment is crucial in the MEA biobanking market as it provides the essential framework for evolving regional healthcare from generic, reactive approaches to precision medicine. Biobanks in the region, such as those in Saudi Arabia (KFSHRC) and the UAE (Abu Dhabi Biobank), facilitate this by offering high-quality biological samples for genomics and pharmaceutical research and development.

MEA Biobanking Market Share, By Settings, 2025 (%)

• Academic Medical Institutions - With a 45% share, academic medical institutions play a dominant role in the market. They are essential for tackling specific regional health issues, such as the high rates of genetic and infectious diseases, by supplying high-quality, well-documented samples for research.
• Pharmaceutical & Biotechnological Companies - Holding a 55% share, the Pharmaceutical & Biotechnological Companies segment is crucial to the MEA biobanking market. It is the main source of demand for high-quality, annotated biospecimens that are used in drug discovery, clinical trials, and personalized medicine. As the region works on diversifying its economy and enhancing healthcare innovation, these companies depend on biobanks to speed up the creation of targeted therapies.

Top Companies in the MEA Biobanking Market

• Thermo Fisher Scientific Inc.
• Tecan Trading AG
• QIAGEN
• Hamilton Company
• Brooks Life Sciences
• TTP Labtech
• VWR International, LLC.
• Promega Corporation
• Worthington Industries
• BD
• Merck KGaA
• Biokryo GmbH
• Cell&Co BioServices
• RUCDR Infinite Biologics
• Modul-Bio

Segments Covered in the Report

By Sample Storage

• Blood
• Cells & Tissues
• Others

By Application

• Regenerative Medicines
• Life Science
• Others

By Settings

• Academic Medical Institutions
• Pharmaceutical & Biotechnological Companies